t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke
Introduction: Acute ischemic stroke (AIS) is a potent trigger of immunosuppression, resulting in increased infection risk. While thrombolytic therapy with tissue-type plasminogen activator (t-PA) is still the only pharmacological treatment for AIS, plasmin, the effector protease, has been reported t...
Main Authors: | Dominik F. Draxler, Felix Lee, Heidi Ho, Charithani B. Keragala, Robert L. Medcalf, Be'eri Niego |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00591/full |
Similar Items
-
A novel ex vivo approach for measuring plasminogen activation upon established plasma clots
by: Jason S. Palazzolo, et al.
Published: (2022-07-01) -
Hyperglycemia aggravates decrease in alpha-synuclein expression in a middle cerebral artery occlusion model
by: Ju-Bin Kang, et al.
Published: (2018-12-01) -
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
by: Niaz Mahmood, et al.
Published: (2018-02-01) -
A meta‐analysis on racial disparity in administration of tissue plasminogen activator (tPA) in stroke patients
by: Muhammad Omar Larik, et al.
Published: (2024-07-01) -
Effect of Fagonia arabica on thrombin induced release of t-PA and complex of PAI-1 tPA in cultured HUVE cells
by: Prutha D. Aloni, et al.
Published: (2016-07-01)